Literature DB >> 12645915

Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan.

Yetrib Hathout1, Kelly Riordan, Marion Gehrmann, Catherine Fenselau.   

Abstract

Analysis of differential protein expression in the cytosol of melphalan-resistant and -susceptible MCF-7 cell lines has been carried out using a combination of two-dimensional gel electrophoresis, mass spectrometry, and bioinformatics. Comparison of multiple digitized gel arrays detected several spots as candidates for differentially expressed proteins in melphalan-resistant MCF-7 cells. The up-regulated proteins included retinoic acid binding protein II, an isoform of the macrophage migration inhibition factor, and other unidentified proteins. The down-regulated proteins included calreticulin, cyclophin A, and an isoform of the 27 kD heat shock protein. Correlation of the differential expression of some of the proteins with acquired resistance of MCF7 cells to melphalan is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12645915     DOI: 10.1021/pr020006i

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  16 in total

1.  Protective role of glycerol against benzene stress: insights from the Pseudomonas putida proteome.

Authors:  Prashanth Bhaganna; Agata Bielecka; Gabriella Molinari; John E Hallsworth
Journal:  Curr Genet       Date:  2015-11-26       Impact factor: 3.886

Review 2.  18O stable isotope labeling in MS-based proteomics.

Authors:  Xiaoying Ye; Brian Luke; Thorkell Andresson; Josip Blonder
Journal:  Brief Funct Genomic Proteomic       Date:  2009-01-16

3.  Comparative proteome analysis of breast cancer and normal breast.

Authors:  Yuanming Luo; Jindan Zhang; Yanxin Liu; Allan Christian Shaw; Xiaorong Wang; Shuzhen Wu; Xuan Zeng; Jie Chen; Youhe Gao; Dexian Zheng
Journal:  Mol Biotechnol       Date:  2005-03       Impact factor: 2.695

4.  Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.

Authors:  Ping Zhou; Julie Teruya-Feldstein; Ping Lu; Martin Fleisher; Adam Olshen; Raymond L Comenzo
Journal:  Blood       Date:  2007-11-02       Impact factor: 22.113

5.  Proteomics: challenges, techniques and possibilities to overcome biological sample complexity.

Authors:  Kondethimmanahalli Chandramouli; Pei-Yuan Qian
Journal:  Hum Genomics Proteomics       Date:  2009-12-08

Review 6.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

7.  Expression of cyclophilin A in gastric adenocarcinoma patients and its inverse association with local relapses and distant metastasis.

Authors:  Evgeniya S Grigoryeva; Nadezhda V Cherdyntseva; Mikhail S Karbyshev; Viktor V Volkomorov; Ivan V Stepanov; Marina V Zavyalova; Vladimir M Perelmuter; Mikhail A Buldakov; Sergey G Afanasjev; Sergey A Tuzikov; Yulia A Bukurova; Nikolai A Lisitsyn; Sergey F Beresten
Journal:  Pathol Oncol Res       Date:  2013-11-24       Impact factor: 3.201

Review 8.  Current implications of cyclophilins in human cancers.

Authors:  Jinhwa Lee; Sung Soo Kim
Journal:  J Exp Clin Cancer Res       Date:  2010-07-19

9.  Downregulation of cyclophilin A by siRNA diminishes non-small cell lung cancer cell growth and metastasis via the regulation of matrix metallopeptidase 9.

Authors:  Zhe Qian; Xiaoting Zhao; Mei Jiang; Wenyun Jia; Chunyan Zhang; Yue Wang; Baolan Li; Wentao Yue
Journal:  BMC Cancer       Date:  2012-10-02       Impact factor: 4.430

10.  Proteome characterization of a human urothelial cell line resistant to the bladder carcinogen 4-aminobiphenyl.

Authors:  Roberta Pastorelli; Federica Saletta; Donatella Carpi; Roberta Campagna; Carlo dell'Osta; Silvia Schiarea; Paolo Vineis; Luisa Airoldi; Giuseppe Matullo
Journal:  Proteome Sci       Date:  2007-05-03       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.